Advertisement
"The Micell DES technology is exciting because it is the first of a newgeneration of stents being developed to precisely deliver a drug while safelyeliminating the polymer faster than any other biodegradable coating that iscommercially available," said Kandzari. "The controlled drug release andkinetics enables a lower drug dose while using known and proven polymers andan approved anti-proliferative drug. Taken together, the Micell DES has thepotential to offer the therapeutic benefit of a drug-eluting stent and thesafety profile of a bare metal stent."
Advertisement
Dr. Kandzari is the Director of Interventional Cardiology Research at theScripps Clinic in La Jolla, CA.
About Micell Technologies
Micell Technologies is a privately-held, early-stage biomedical companydedicated to applying its unique surface and polymer modification technologiesfor improved patient benefits for medical device and drug deliveryapplications. Its first product, MiStent(TM), is a rapid absorbing coateddrug-eluting stent (DES) with precise control of drug release andpharmacokinetics. To learn more, please visit our website athttp://www.micell.com.
Contact: James McClain Ph.D., Chief Technology Officer
Micell Technologies: (919) 313-2111
SOURCE Micell Technologies
